In a report released yesterday, David Larsen from BTIG maintained a Buy rating on Healthequity (HQY - Research Report), with a price target of $85.00. The company's shares closed yesterday at $63.44.According to TipRanks, Larsen is an analyst with an average return of -8.5% and a 34.76% success rate. Larsen covers the Technology sector, focusing on stocks such as Omnicell, Health Catalyst, and Sharecare.Healthequity has an analyst consensus of Moderate Buy, with a price target consensus of $75.00, a 18.22% upside from current levels. In a report released on September 2, Barrington also reiterated a Buy rating on the stock with a $75.00 price target.
https://www.tipranks.com/news/blurbs/healthequity-hqy-receives-a-buy-from-btig?utm_source=advfn.com&utm_medium=referral